All In Biotech

Drug Trial Radar · NCT06346340

A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy

A Phase 4, Multicenter, Open-Label Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/ Keratometry and Postoperative Refractive Accuracy

Last checked: Nov 20, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

97

Actual

Start

Apr 30, 2024

Primary completion

Feb 24, 2025

Study completion Feb 24, 2025

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Apr 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 4, Multicenter, Open-Label Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/ Keratometry and Postoperative Refractive Accuracy

Conditions

  • Dry Eye

Interventions

  • MieboDrug

    Miebo applied in both eyes 4 times per day for approximately 30 days before cataract surgery. Following the completion of the standard follow up, approximately 30 days after cataract surgery, subjects will begin a second regimen of Miebo , 4 times per day in both eyes, for approximately 30 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Difference Between Absolute Deviations From Predicted Refractive Error in the Study Eye.Time frame: Assessed at Postop Day 30 ± 7 days

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Site 105

    Laguna Hills, California

  • Site 102

    Petaluma, California

  • Site 109

    Sacramento, California

  • Site 111

    Grand Junction, Colorado

  • Site 103

    Largo, Florida

  • Site 106

    Oak Lawn, Illinois

  • Site 108

    Alexandria, Minnesota

  • Site 104

    St Louis, Missouri

  • Site 101

    Somersworth, New Hampshire

  • Site 107

    Sioux Falls, South Dakota

  • Site 110

    San Antonio, Texas

  • Site 112

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.